Cabenuva vs Sunlenca
A side-by-side look at two hiv medications advertised on TV. Informational only — not medical advice.
| US Cabenuva | US Sunlenca | |
|---|---|---|
| Generic name | cabotegravir/rilpivirine | lenacapavir |
| Drug class | Integrase Inhibitor / NNRTI (Long-Acting Injectable) | Capsid Inhibitor |
| Treats | HIV-1 infection | Multidrug-resistant HIV |
| Category | HIV | HIV |
| Manufacturer | ViiV Healthcare | Gilead Sciences |
| Year approved | 2021 | 2022 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Injection site reactions, Fever, Fatigue, Headache | Injection-site reactions, Nausea, Headache, Risk of resistance if doses are missed |
Frequently asked questions
Is Cabenuva or Sunlenca better?
Neither is universally "better." Cabenuva (cabotegravir/rilpivirine) and Sunlenca (lenacapavir) are both used for hiv, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Cabenuva and Sunlenca?
Cabenuva is a Integrase Inhibitor / NNRTI (Long-Acting Injectable) made by ViiV Healthcare, while Sunlenca is a Capsid Inhibitor made by Gilead Sciences. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Cabenuva has the larger estimated TV advertising budget of the two.